Lineage Cell Therapeutics (NYSE:LCTX) said on Monday the United States Patent and Trademark Office had issued a notice of allowance to two patents for the company's application with claims covering manufacturing processes for its oligodendrocyte progenitor cell therapy candidate (OPC1) for the treatment of spinal cord injury.
The patent, which is expected to be issued in the coming months, would have a term that would expire no earlier than 2040.
Lineage aims to provide cell-based therapy to patients by replacing cells lost due to disease, aging, or in the case of spinal cord injury.
The Company currently is focused on preparing for a planned interaction with the U.S. Food and Drug Administration this quarter to discuss its OPC1 Investigational New Drug (IND) amendment submission.